

October 11, 2006

To Whom It May Concern

Company: Taisho Pharmaceutical Co., Ltd.
Representative: Akira Uehara, President
(First Section of TSE: Code 4535)
Contact: Makoto Funahashi, General Manager
Public Relations Section
(Tel: +81-3-3985-1115)

Taisho to Repurchase Treasury Stock
(Treasury stock repurchase based on the Articles of Incorporation
as stipulated by Article 165, Paragraph 2 of the Japanese Corporation Act)

Taisho Pharmaceutical Co., Ltd. has announced that its Board of Directors today passed a resolution to repurchase treasury stock, as detailed below. This repurchase is based on the provisions of Article 156 of the Japanese Corporation Act, which has been reinterpreted and applied in accordance with Article 165, Paragraph 3 of the same Act.

1. Reason for repurchase of treasury stock

The repurchase of treasury stock will allow for a flexible implementation of capital policy in response to changes in the business environment.

2. Details of repurchase

(1) Type of stock:	Taisho Pharmaceutical common stock
(2) Amount of stock:	8,500,000 shares (upper limit) (percentage of total number of shares issued: 2.65%)
(3) Total value of stock:	¥22,000 million (upper limit)
(4) Period of repurchase:	From October 12, 2006 to May 31, 2007

Notes:

Treasury stock holdings as of September 30, 2006	
Total number of shares issued (excluding treasury stock):	308,142,822 shares
Number of shares of treasury stock:	12,322,688 shares